Investigational Drugs
Investigational drugs for NAFLD are derived from global clinical trials with the latest progress, and detailed drug properties are extracted from DrugBank and PubChem. For each drug, related therapeutic strategies, targets, and clinical trials in NAFLDkb are presented with knowledge graphs.
stats1
stats2
Search for:
Pioglitazone5 records.
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D237 | Nesinaact | Chemical drug | -- | CD26 antigen inhibitor; PPARG agonist | Improve insulin resistance | Under clinical trials | Details |
| D275 | Pioglitazone | Chemical drug | DB01132 | PPARG agonist | Improve insulin resistance | Advanced in clinical trials | Details |
| D378 | Troglitazone | Chemical drug | DB00197 | PPARG agonist; PPARD; PPARA | Improve insulin resistance | Under investigation | Details |
| D388 | Vitamin E | Supplement | DB00163 | NR1I2; ALOX5; DGKA | Anti-inflammatory | Under clinical trials | Details |
| D443 | Pioglitazone plus Empagliflozin | Combinatory | -- | Thiazolidinediones (TZD) & SGLT2i | -- | Under clinical trials | Details |